Agenda
7:00 AM — 8:00 AM
8:00 AM — 8:20 AM
Welcoming Remarks8:20 AM — 8:45 AM
Opening and Introduction to the Conference10:30 AM — 11:00 AM
11:00 AM — 12:30 PM
Session 2: Role of Clinical Trials in Biosimilar Development12:30 PM — 1:30 PM
1:30 PM — 2:45 PM
Session 3: Impact of US FDA Final Naming Guidance for Biologics3:30 PM — 3:45 PM
3:45 PM — 5:30 PM
Session 5: Penetrating the Market5:30 PM — 6:30 PM
7:00 AM — 8:00 AM
8:00 AM — 8:10 AM
Opening Remarks10:10 AM — 10:30 AM
10:30 AM — 11:15 AM
Session 7: Ask the Regulators11:15 AM — 12:15 PM
Session 8: Postmarketing Phase: Approval is Just the Beginning12:15 PM — 1:30 PM
1:30 PM — 3:00 PM
Session 9: Interchangeability3:00 PM — 3:30 PM
Closing Remarks¿Tiene una cuenta?